ITI Pharma & Healthcare Fund(IDCW)
Ticker: mf16932
Decent
68/100
☆ Add to Watchlist
More Options
I
ICICI Pru Nifty LargeMidcap 250 Index Fund(IDCW)
The fund presents a decent investment opportunity with a balanced exposure to growth and stability, but investors should be cautious of market risks.
View details
I
ICICI Pru Nifty LargeMidcap 250 Index Fund(IDCW Payout)
The ICICI Pru Nifty LargeMidcap 250 Index Fund presents a decent investment opportunity with a balanced risk-reward profile, but investors should be cautious of market volatility.
View details
C
Canara Rob Banking and PSU Debt Fund(IDCW)
The fund shows potential but is hindered by inconsistent growth and profitability metrics, along with governance concerns.
View details
S
SBI Equity Minimum Variance Fund(IDCW-Payout)
The SBI Equity Minimum Variance Fund shows decent potential but is not without its risks. Investors should weigh the moderate growth and profitability against the valuation and governance concerns.
View details
S
SBI Equity Minimum Variance Fund(IDCW)
The SBI Equity Minimum Variance Fund shows decent potential with consistent growth and profitability metrics, but some risks in governance and execution should be monitored.
View details
A
Aditya Birla SL Dynamic Asset Allocation Omni FOF(IDCW)
The fund shows decent potential with a balanced approach, but attention should be paid to execution risks and market sentiment.
View details
A
Aditya Birla SL Dynamic Asset Allocation Omni FOF(IDCW Payout)
The fund shows decent potential with a balanced approach to growth and risk management, though some areas require attention.
View details
P
PGIM India Money Market Fund(DD-IDCW)
The fund shows decent potential but lacks strong growth drivers and has some risks associated with profitability and governance.
View details
P
PGIM India Money Market Fund(M-IDCW)
The fund shows decent stability but lacks strong growth drivers, making it a cautious investment.
View details
P
PGIM India Money Market Fund(W-IDCW)
The fund is positioned in a stable sector with decent growth prospects, but it faces challenges in profitability and governance that could impact future performance.
View details
Q
Quantum ELSS Tax Saver Fund(IDCW)
The Quantum ELSS Tax Saver Fund shows decent potential with consistent growth and a strong governance structure, but there are some risks related to execution and liquidity.
View details
A
Aditya Birla SL Global Excellence Equity FoF(IDCW)
The fund shows potential but carries risks that may affect future performance. Caution is advised.
View details
A
Aditya Birla SL Global Excellence Equity FoF(IDCW-Payout)
The fund shows potential but faces challenges in profitability and growth consistency. Caution is advised.
View details
B
Baroda BNP Paribas Dynamic Bond Fund(W-IDCW)
The fund shows decent potential but faces challenges in profitability and growth drivers.
View details
B
Baroda BNP Paribas Dynamic Bond Fund(Q-IDCW)
The fund shows decent potential with stable growth but has some risks that need to be monitored.
View details
B
Baroda BNP Paribas Dynamic Bond Fund(M-IDCW)
The fund shows decent potential with stable growth and profitability metrics, but some execution risks need to be monitored.
View details
Business Overview
The ITI Pharma & Healthcare Fund (IDCW) is a focused mutual fund designed for investors looking to capitalize on the growth potential of the pharmaceutical and healthcare sectors in India. This fund is ideal for those seeking long-term capital appreciation through investments in high-quality companies within these industries. With a robust management team and a strategic investment approach, it aims to deliver sustainable returns while managing risks effectively.
- Focus on pharma and healthcare sectors
- Ideal for long-term capital appreciation
- Managed by experienced professionals
- Diversified portfolio for risk management
- Aligned with India's growing healthcare demand
Investment Thesis
ITI Pharma & Healthcare Fund stands out due to its strong promoter credibility, robust growth potential in digital services, and attractive valuation compared to peers. This combination positions the fund as a compelling investment opportunity for retail investors seeking exposure in the healthcare sector.
- Strong backing from a reputable promoter group ensures stability and trust.
- Significant growth potential in digital healthcare services driven by increasing demand.
- Attractive valuation metrics compared to industry peers enhance investment appeal.
- Focus on innovative healthcare solutions positions the fund for long-term growth.
- Diversified portfolio mitigates risks while capitalizing on market opportunities.
Peer Perspective
ITI Pharma & Healthcare Fund currently trades at a slight premium compared to peers like SBI Healthcare Opportunities Fund and HDFC Healthcare Fund. A sustained improvement in margin stability could trigger a favorable rerating.
📊 Stock Investment Checklist (100 Points)
ITI Pharma & Healthcare Fund(IDCW) • Updated: 2025-10-01 06:22:50
-
10BusinessHighPharmaceutical sector shows potential but faces regulatory challenges.
-
10GrowthHighModerate revenue growth observed, but profit margins are inconsistent.
-
10ProfitabilityHighROE and ROCE are below industry average, cash flow is stable.
-
8ValuationHighP/E ratio is higher than peers, indicating potential overvaluation.
-
6BalanceGoodDebt levels are manageable, but liquidity is a concern.
-
7GovernanceHighPromoter holding is decent, but some pledging raises concerns.
-
5DriversGoodGrowth drivers are present but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The fund shows potential in the pharma sector, but faces challenges in profitability and valuation metrics.